Single-cell proteomics identifies leukemia landscape associated with clinical outcomes in R/R AML treated with MDM2I (MILADEMETAN) and FLT3I (QUIZARTINIB): Putative role of CD68 and diversity index

Category Primary study
JournalBlood
Year 2021
This article has no abstract
Epistemonikos ID: 509c89c47601ef9d3818095c68de8d8a121f9da0
First added on: Feb 13, 2025